Patients in Scotland with advanced prostate cancer will be able to get routine access to Sanofi Genzyme’s Jevtana on the NHS after all, after cost regulators changed track and endorsed the drug as a cost effective use of resources.
Read More
Cost regulators have approved the use of four new medicines for use by NHS Scotland, including a new option for Parkinson’s disease and asthma, but rejected Sanofi-Genzyme’s Jevtana for prostate cancer and Amgen’s Repatha for high cholesterol.
Read More
The National Institute for Health and Care Excellence has now published guidance supporting the NHS use of Sanofi Genzyme’s plant-based chemotherapy Jevtana for prostate cancer.
Read More
